IO BIOTECH INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
IO BIOTECH INC. - More news...
IO BIOTECH INC. - More news...
- IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center
- IO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC 2023 World Conference on Lung Cancer
- IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer
- IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone
- IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead
- IO Biotech to Present at the Jefferies Healthcare Conference
- IO Biotech Announces 2023 First-Quarter Results
- IO Biotech Announces 2022 Fourth-Quarter and Year-End Results
- IO Biotech to Participate in March 2023 Investor Conferences
- IO Biotech Announces Appointment of Devin Smith as General Counsel
- IO Biotech Provides Business Update
- IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
- IO Biotech Announces Third Quarter Results for 2022
- IO Biotech to Participate in the Jefferies London Healthcare Conference
- IO Biotech Announces Appointment of New Chief Financial Officer
- IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
- IO Biotech to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
- IO Biotech Announces Second Quarter Results for 2022
- IO Biotech to Participate in the 2022 BIO International Convention
- IO Biotech Announces Two Presentations at the American Society of Clinical Oncology Annual Meeting 2022
- IO Biotech to Participate in the Jefferies Healthcare Conference
- IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanoma
- IO Biotech Announces First Quarter Results for 2022
